Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jan Sermon"'
Autor:
Nicolas Girard, Keunchil Park, Se-Hoon Lee, Santiago Viteri, Claudio A. Schioppa, Joris Diels, Mustafa Oguz, Bernardo H. Rodrigues, Nora Rahhali, Jan Sermon, Francesca Ghilotti, Tracy Li, Meena Thayu, Roland E. Knoblauch, Parthiv Mahadevia, Byoung Chul Cho
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100832- (2024)
Background: Amivantamab, an EGFR-MET bispecific antibody, is the first approved targeted therapy for patients with EGFR Ex20ins NSCLC after prior platinum-based chemotherapy—a population with historically poor outcomes before amivantamab approval.
Externí odkaz:
https://doaj.org/article/b0e636fa219d41078d74b8b155ecc004
Autor:
Petros Christopoulos, Nicolas Girard, Claudia Proto, Marta Soares, Pilar Garrido Lopez, Anthonie J. van der Wekken, Sanjay Popat, Joris Diels, Claudio A. Schioppa, Jan Sermon, Nora Rahhali, Corinna Pick-Lauer, Agnieszka Adamczyk, James Penton, Marie Wislez
Publikováno v:
Cancers, Vol 15, Iss 22, p 5326 (2023)
Patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor gene (EGFR) Exon 20 insertions (Exon20ins) at the second line and beyond (2L+) have an unmet need for new treatment. Amivantamab, a bispecific EGFR- and M
Externí odkaz:
https://doaj.org/article/d617c8cd24e7487f80dbdd4481492e54
Autor:
Flore Decuypere, Jan Sermon, Paul Geerts, Tom R Denee, Cedric De Vos, Bart Malfait, Mark Lamotte, Cornelis L Mulder
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179049 (2017)
Achieving greater continuation of treatment is a key element to improve treatment outcomes in schizophrenia patients. However, reported treatment continuation can differ markedly depending on the study design. In a retrospective setting, treatment co
Externí odkaz:
https://doaj.org/article/a19dba64ae03457abb03d671e385a250
Autor:
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J. Perualila, Claudio A. Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
Publikováno v:
Advances in Therapy. 40:1187-1203
Autor:
Suzy Van Sanden, Molly Murton, Anna Bobrowska, Nora Rahhali, Jan Sermon, Bernardo Rodrigues, Danielle Goff-Leggett, Christos Chouaid, Martin Sebastian, Alastair Greystoke
Publikováno v:
Targeted Oncology. 17:153-166
Information on the epidemiology of uncommon EGFR mutations including exon 20 insertions amongst non-small-cell lung cancer (NSCLC) is lacking.The objective of this pragmatic literature review (PLR) and meta-analysis was to generate robust prevalence
Autor:
Heidi Taipale, Erik Jedenius, Dana Enkusson, Syed Rahman, Jan Sermon, Juha Mehtälä, Amy Leval, Fabian Hoti, Antti Tanskanen, Jari Tiihonen, Ellenor Mittendorfer-Rutz
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports
Scientific Reports
This study aimed to identify if antipsychotic exposure in offspring is associated with psychiatric and non-psychiatric healthcare service use and work disability of their parents. This Swedish population-based cohort study was based on data comprisin
Autor:
Joris Diels, Jan Sermon, Dominic Pilon, Stéphane Oudard, Martin Ladouceur, Hiroji Uemura, Ajay S. Behl, Boris Hadaschik, Jinan Liu, Suzy Van Sanden, L. Dearden, Steven Joniau, Simon Chowdhury
Publikováno v:
Advances in Therapy
Introduction Apalutamide and enzalutamide are next-generation androgen receptor inhibitors that demonstrated efficacy in placebo-controlled studies (SPARTAN for apalutamide; PROSPER for enzalutamide) when used in combination with androgen deprivation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e08e47107b8c90d31d1e67bdeec4d779
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85076552283
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85076552283
Autor:
Dominic Pilon, Jan Sermon, Stéphane Oudard, Joris Diels, Jinan Liu, L. Dearden, Hiroji Uemura, Kelly McQuarrie, Boris Hadaschik, Suzy Van Sanden, Steven Joniau, Simon Chowdhury, Patrick Lefebvre
INTRODUCTION: The present study aimed to indirectly compare apalutamide and enzalutamide with respect to tolerability and health-related quality of life (HRQoL) among men with non-metastatic castration-resistant prostate cancer (nmCRPC). METHODS: Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fd6282459a47d5c02961d505eb4a21f
https://lirias.kuleuven.be/handle/20.500.12942/695066
https://lirias.kuleuven.be/handle/20.500.12942/695066
Autor:
Antti Tanskanen, Erik Jedenius, Syed Rahman, Jan Sermon, Maila Majak, Juha Mehtälä, Fabian Hoti, Dana Enkusson, Heidi Taipale, Amy Leval, Jari Tiihonen, Ellenor Mittendorfer-Rutz
Publikováno v:
Schizophr Bull
Background The study aimed to (1) compare the risk of health care use, adverse health status, and work productivity loss of parents of patients with schizophrenia to parents of patients with multiple sclerosis (MS), rheumatoid arthritis (RA), epileps
Autor:
Jan Sermon, Heidi Taipale, Maila Majak, Fabian Hoti, Antti Tanskanen, Jari Tiihonen, Ellenor Mittendorfer-Rutz, Amy Leval, Kristina Alexanderson, Dana Enkusson, Juha Mehtälä, Erik Jedenius
Publikováno v:
Schizophrenia Research. 197:274-280
Introduction It has remained controversial if antipsychotic treatment is associated with increased or decreased mortality among patients with schizophrenia, and if there are any clinically meaningful differences between specific agents and routes of